Melanotan II (MT-II) is a synthetic, cyclic heptapeptide analogue of alpha-melanocyte stimulating hormone (α-MSH) developed at the University of Arizona in the late 1980s. It acts as a non-selective agonist at melanocortin receptors MC1R, MC3R, MC4R, and MC5R, making it a broad pharmacological tool for investigating the melanocortin system across multiple physiological processes.
MT-II was developed by Victor Hruby, Mac Hadley, and colleagues at the University of Arizona as part of a program seeking potent, stable melanotropic peptides for research into melanin production and photoprotection. The structure — Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂ — introduces several modifications over α-MSH: norleucine replaces methionine at position 4 (improving oxidative stability), D-phenylalanine increases receptor affinity and potency, and cyclisation via a lactam bridge between Asp and Lys dramatically extends half-life compared to the linear endogenous peptide.
The resulting compound has approximately 1000× greater potency than α-MSH at MC1R and markedly improved plasma stability, making it a more tractable research tool for in-vivo studies.
The five melanocortin receptor subtypes have distinct tissue distributions and physiological roles:
The University of Arizona group demonstrated that systemic MT-II administration in Caucasian volunteers produced dose-dependent skin tanning without UV exposure. Hadley et al. (1998) showed MT-II at 0.025 mg/kg subcutaneously produced visible increases in skin pigmentation over 2 weeks in fair-skinned subjects. This drove interest in melanocortin agonists as potential photoprotective agents for individuals at high UV-induced melanoma risk.
A key observation was that MT-II-induced pigmentation was rapid-onset and faded over weeks following discontinuation — consistent with stimulation of existing melanocyte activity rather than melanocyte proliferation. This has implications for research into melanocyte biology and MC1R pharmacology.
In preclinical rat studies, MT-II produced dose-dependent pro-erectile effects mediated via spinal MC4R signalling. Wessells et al. (1998, 2000) conducted the first human trials, demonstrating that MT-II produced penile erections in men with psychogenic or organic erectile dysfunction — effects not blocked by the PDE5 pathway, suggesting a central mechanism distinct from that of PDE5 inhibitors.
PT-141 (bremelanotide) was subsequently developed as a more selective derivative for sexual dysfunction, and was eventually approved by the FDA for hypoactive sexual desire disorder in women (Vyleesi, 2019) — marking the first approved drug from the MT-II programme.
MT-II administration in rodent models produces marked, dose-dependent reductions in food intake through MC3R and MC4R-mediated signalling in the hypothalamus. This appetite suppression effect is well-replicated and forms the basis of research into melanocortin agonists for obesity treatment. MC4R knockout mice are obese and hyperphagic, confirming the central role of this receptor in energy homeostasis.
Human studies with MT-II consistently reported nausea as the primary dose-limiting side effect, particularly at higher doses. This is attributed to MC4R activation in the dorsal vagal complex (area postrema), a known chemoreceptor trigger zone. This side effect profile led researchers to explore more selective compounds targeting specific receptor subtypes.
